Detailed Information on Publication Record
2018
Colicin F-Y inhibits pathogenic Yersinia enterocolitica in mice
BOSÁK, Juraj, Lenka MICENKOVÁ, Matěj HRALA, Katarína POMORSKÁ, Michaela BOSÁKOVÁ et. al.Basic information
Original name
Colicin F-Y inhibits pathogenic Yersinia enterocolitica in mice
Authors
BOSÁK, Juraj (703 Slovakia, belonging to the institution), Lenka MICENKOVÁ (703 Slovakia, belonging to the institution), Matěj HRALA (203 Czech Republic, belonging to the institution), Katarína POMORSKÁ (703 Slovakia, belonging to the institution), Michaela BOSÁKOVÁ (203 Czech Republic, belonging to the institution), Pavel KREJČÍ (203 Czech Republic, belonging to the institution), Eduard GÖPFERT (203 Czech Republic), Martin FALDYNA (203 Czech Republic) and David ŠMAJS (203 Czech Republic, guarantor, belonging to the institution)
Edition
Scientific reports, London, NATURE PUBLISHING GROUP, 2018, 2045-2322
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10601 Cell biology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 4.011
RIV identification code
RIV/00216224:14110/18:00101322
Organization unit
Faculty of Medicine
UT WoS
000441775900006
Keywords in English
Yersinia enterocolitica; Colicin F-Y
Tags
International impact, Reviewed
Změněno: 26/3/2019 10:26, Soňa Böhmová
Abstract
V originále
Yersiniosis belongs to the common foodborne diseases around the world, and frequently manifests as diarrhea that can be treated with probiotics. Colicin F-Y is an antibacterial agent produced by bacteria and it is capable of specific growth inhibition of Yersinia enterocolitica, the causative agent of gastrointestinal yersiniosis. In this study, recombinant E. coli producing colicin F-Y were constructed, using both known probiotic strains EcH22 and EcColinfant, and the newly isolated murine strains Ec1127 and Ec1145. All E. coli strains producing colicin FY inhibited growth of pathogenic Y. enterocolitica during co-cultivation in vitro. In dysbiotic mice treated with streptomycin, E. coli strains producing colicin F-Y inhibited progression of Y. enterocolitica infections. This growth inhibition was not observed in mice with normal gut microflora, likely due to insufficient colonization capacity of E. coli strains and/or due to spatial differences in intestinal niches. Isogenic Y. enterocolitica producing colicin F-Y was constructed and shown to inhibit pathogenic Y. enterocolitica in mice with normal microflora. Evidence of in vivo antimicrobial activity of colicin F-Y may have utility in the treatment of Y. enterocolitica infections.
Links
EF16_013/0001761, research and development project |
| ||
GA16-21649S, research and development project |
| ||
LM2015051, research and development project |
| ||
ROZV/25/LF/2017, interní kód MU |
|